Background. Limited viral load (VL) testing in human immunodeficiency virus (HIV) treatment programs in low-income countries often delays detection of treatment failure. The impact of remaining on failing protease inhibitor (PI)-containing regimens is unclear.
studies have been cross-sectional with time since failure not known [4, 5, [7] [8] [9] or have been conducted in high-income countries, where patients spend little time on failing regimens [10, 11] .
Here we explore the evolution of VL and PI resistance following virological failure in patients randomized to second-line PI monotherapy in the Europe-Africa Research Network for Evaluation of Second-line Therapy (EARNEST) trial, a pragmatic trial of second-line ART in sub-Saharan Africa. Although PI monotherapy is clearly not an appropriate therapeutic option, PIs remain the cornerstone of second-line therapy. As the accumulation of viral resistance among patients on monotherapy is likely more rapid than among patients on combination therapy, our analyses provide an upper bound on the impact of the latter. The specific aims were to determine whether darunavir retains sufficient activity to be a viable third-line treatment option; whether previous mutations affect the rate of development and nature of future mutations; and to determine the effect of mutations on viral load.
METHODS
EARNEST randomized participants in Uganda, Zimbabwe, Malawi, Kenya, and Zambia failing first-line therapy (based on clinical, immunological, and/or virological criteria, all confirmed by VL >400 copies/mL) to receive a PI (ritonavir-boosted lopinavir) plus 2-3 NRTIs, raltegravir, or alone as monotherapy following an initial induction with 12 weeks' raltegravir [12] . Patients were followed for 144 weeks from switch to second-line with scheduled visits every 4-8 weeks. Adherence was assessed by structured questions; additional adherence counseling (approach at the discretion of the clinical sites, tailored to the individual patient) was given when lapses were identified. Treatment was monitored clinically and with CD4 counts every 12-16 weeks. VL was measured retrospectively and monitored by the data monitoring committee (DMC), but results were not available to clinicians. In May 2013, on reviewing week 96 data, the DMC recommended that patients on PI monotherapy should resume combination therapy due to inferior viral suppression and greater PI resistance compared to PI + NRTI.
This study included patients randomized to PI monotherapy from the start of PI monotherapy (post-raltegravir induction) to the earliest of their last clinic visit or stopping PI monotherapy for >31 days.
Plasma samples were stored at weeks 4, 12, 24, 36, 48, 64, 80, 96, 112, 128, 136 , and 144. VL was measured at weeks 96 , and 144 in all PI monotherapy patients, additionally at weeks 64, 80, 112, and 128 in those with VL >400 copies/mL at weeks 48 and/or 96, and at week 112 or 128 when this was the last visit before return to combination therapy. VL was assayed retrospectively in batches using the Abbott RealTime HIV-1 assay in a central laboratory (Joint Clinical Research Centre [JCRC], Kampala, Uganda).
Protease genotyping was performed on all samples with VL >1000 copies/mL obtained at week 48, 96, or 144. Additional genotyping was performed on all samples after week 24 with VL >1000 copies/mL in patients with PI mutations at week 48 and/or 96, and on any week 112 or 128 samples with VL >400 copies/mL when that was the last sample before returning to combination therapy. In total, 337 of 363 (93%) genotypes were performed at Virco (Beerse, Belgium) and 26 (7%) (from 1 site with delayed shipping) at a WHO-designated and College of American Pathologists-accredited laboratory (JCRC, Kampala, Uganda) (see Supplementary Data for details of the methods used at each laboratory). PI mutations were defined following the International Antiviral Society-USA [13] , excluding minor PI polymorphisms not associated with drug resistance, following WHO recommendations [14] . Susceptibility was predicted using the Stanford algorithm version 7.0, on full sequence data [15] . Subtype was determined by the REGA algorithm version 3.0.9 [16] . Sequences were submitted to GenBank (accession numbers MG549462-MG549824).
Statistical Analysis
We defined virological failure as failure to suppress VL <1000 copies/mL by week 24 (12 weeks after stopping raltegravir induction), confirmed VL >1000 copies/mL (first sample as date of failure), or final VL >1000 copies/mL (unconfirmed).
Patients were PI naive at trial entry (no protease genotypes performed at enrollment); we therefore considered PI mutations absent in genotypes as absent at previous time points when genotypes were not assayed since intermediate time points were only assayed if PI mutations were detected at weeks 48/96. Sensitivity analyses did not carry absence of PI mutations backward or included only week 48, 96, and 144 samples.
We used univariable and multivariable logistic regression to explore associations between PI mutations at failure and adherence and viral subtype. Backward elimination (exit P > .1) was used to adjust for confounders, including patient demographics (age, sex), characteristics at second-line switch (log 10 VL, CD4, time on first-line ART), and characteristics on second-line ART before failure (proportion of samples with VL >50 copies/mL, log 10 virological copy-years [17] , time on PI monotherapy). Adherence was defined by the proportion of previous visits on second-line treatment with self-reported nonadherence or not adhering to the trial visit schedule. Fractional polynomials were used to incorporate nonlinearity of continuous factors. This analysis included 72 patients with genotypes at failure (Supplementary Table 1 ) and 35 patients who did not have a genotype at failure but had no PI mutations in their first observed genotype (107 total).
After failure we analyzed accumulation of PI mutations, including mutations that had been observed previously, assuming they were archived in the viral reservoir (so total mutation counts never decreased). Mutations present in 1 sample were rarely absent in subsequent samples; this occurred 49 times across 440 mutations with subsequent samples postdetection (mean, 2.17 postdetection samples per mutation totaling 956 tests).
Associations between each mutation that appeared in at least 5 patients and the presence of other mutations in the previous sample were assessed using exact logistic regression.
We modeled the rate of mutation development using Poisson models, forcing into the model key exposures time since failure, adherence, subtype, and number of PI mutations in the previous sample. Backward elimination was used as above, including additional factors: VL at second-line failure, previous VL, and previous CD4. Adherence was time-updated. Interactions with time since failure were retained if P < .05.
Change in log 10 VL postfailure was modeled using linear-mixed-effect models with random effects for patient and time since failure (unstructured covariance). Associations were explored as for mutation development excluding previous VL and VL at switch to second-line treatment. Viremia copy-years before failure and time on second-line treatment before failure were co-linear (Spearman correlation = 0.84) with opposing effects in the final model; only time on second-line therapy before failure was retained due to its superior fit.
RESULTS
We randomized 418 patients failing first-line therapy (43% with VL >100 000 copies/mL; 62% with CD4 <100 cells/μL) to PI monotherapy. Three hundred eighty-six (92%) had at least 1 VL from week 24 and were considered for inclusion in this analysis (Supplementary Figure 1) Virological failure occurred in 134 of 386 (34%) patients, with genotypes at or after failure for 118 of 134 (88%). These 118 patients experienced virological failure after a median of 36 (IQR, 12-68) weeks on PI monotherapy and were followed for a median of 68 (IQR, 48-88) weeks subsequently. One hundred four (88%) reintroduced combination therapy at trial exit or following DMC recommendations and 8 (7%) following clinical/ immunological failure; 4 died (Table 1) . Mortality, WHO stage 4 clinical events, and CD4 response was similar to the standardof-care PI + NRTI arm at week 96/144 [12, 18] . Three hundred sixty-three of 572 (62%) genotypes were available from samples stored at or after failure (Supplementary Table 1) , with a median of 3 (IQR, 2-4) genotypes per patient.
Overall, 86 of 118 (73%) patients developed at least 1 PI mutation. The most common were M46I, I54V, and V82A, present in 11 of 114 (10%), 14 of 112 (13%), and 13 of 113 (12%) patients, respectively, at failure (Figure 1 ), rising to 23 of 77 (30%), 34 of 79 (43%), and 31 of 77 (40%), respectively, 40-48 weeks after failure (denominators vary due to assumptions that absent mutations were absent in previous ungenotyped samples and that mutations accumulate).
Development of I47A was associated with the absence of I54V in the previous sample (odds ratio Table 3) .
After 40-48 weeks of failure, 13 of 58 (22%) patients had no mutations, and 17 of 58 (25%) had ≥4 mutation (Figure 3) . On average, patients developed 1.7 (95% CI, 1.5-2.0) new mutations per year. In a multivariable model (Table 2) , a second mutation developed faster than the first, but subsequent mutations took progressively longer to emerge than the second (P < .0001). Mutations emerged faster in those with higher CD4 counts in their previous sample (P = .03), who were older (P = .0002), and with longer times since failure (P = .01). There was no evidence of associations with adherence (P = .67), and a weak effect of subtype (P = .11) and VL at switch to second-line therapy (P = .07). There was no evidence that any specific mutation had a different effect than the average mutation effect (P > .12) or of any effect changing over time (interaction P > .08). Substituting resistance to lopinavir for number of mutations in the previous sample, there was borderline evidence that a higher level of resistance to lopinavir in the previous sample reduced the rate of development of subsequent mutations (P = .03; Supplementary Table 4 ).
The median VL at failure was 3725 (IQR, 1941-15 024) copies/mL (Table 1) , increasing by 0.51 (95% CI, .34-.67; P < .0001) log 10 copies/mL per year of postfailure follow-up. VL increased with each new PI mutation (P = .0002; Table 3 and Supplementary Figure 2 ) with a significantly larger increase associated with I47A (P = .003; heterogeneity vs other mutations P = .05). Higher self-reported adherence (P = .006), more time on second-line ART before failure (P = .005), more time on first-line ART (P = .02), and older age (P = .03) were associated with lower VL. There was no association with subtype (P = .45). VL plateaued after the development of I47A (-0.42 [95% CI, -.99 to +0.14] log 10 copies per year vs +0.29 [95% CI, +.12 to +.46] log 10 copies per year without I47A; interaction P = .01; Supplementary Table 5 ; no modification of effect on VL when I47A was combined with V32I, interaction P = .95).
All results were similar not carrying the absence of mutations backward (Supplementary Figures 3-4 and Supplementary  Tables 6-8 ).
DISCUSSION
In this study of VL failure on lopinavir monotherapy, we found that patients often failed without PI mutations, but that resistance accumulated with longer time on the failing regimen. Most patients retained susceptibility to darunavir up to 1 year after failure and VL increases were modest.
Approximately 20% of patients had intermediate/high-level lopinavir resistance at virological failure, rising to approximately 70% 1 year postfailure. As the proportion with comparable atazanavir resistance was only about 10%-20% lower at the same time points, there would be little advantage in switching empirically (ie, without resistance testing) from lopinavir to atazanavir after treatment failure, other than for possible advantages of convenience or tolerability that might improve adherence and hence viral suppression. However, more than half of all patients had virus that remained fully susceptible to darunavir 1 year after failure, supporting its suitability as a potential third-line option. Other studies have noted this [4, 5, 7] , but our much larger sample size and more frequent sampling allowed more accurate assessment of resistance evolution and greater confidence in the findings. The benefit of resistance testing in this setting is uncertain [19] . Testing may identify some patients with no PI resistance who might resuppress with additional adherence counseling [20] , delaying the need to switch to a costly third-line regimen. The few patients that have developed darunavir resistance may benefit from a nonstandard third-line regimen, if available.
Many patients had virological failure without resistance, a well-known finding for PI-based regimens [4, [21] [22] [23] . Mutations in other viral regions (eg, gag) [21, [24] [25] [26] and adherence [20] have both been suggested as causes. We found no evidence that adherence affected resistance at failure, and the low median VL at failure suggests the cause is unlikely to be due to complete nonadherence. Adherence support was provided throughout this trial [20] and importantly, most resuppressed after NRTIs were reintroduced [18] .
Our finding of low prevalence of mutations/resistance at failure followed by progressive accumulation is consistent with studies of PI-based combination regimens in high-and low-income countries [5, 10] . Our study size allowed us to explore factors associated with mutation rate to a greater degree than previously possible. The main factor accelerating mutation development was the number of prior PI mutations. This relationship was complex, with the rate increasing after the first mutation, but then subsequently decreasing with additional mutations (ie, reaching a "ceiling" effect). This may be mediated through the effects of mutations on variability in the virus population [25, 27] . It may also indicate the balance between maintaining replicative capacity and overcoming drug presence (a fitness effect; see below). Previous studies have noted this "ceiling effect" [28] , and found the rate increased after the first mutation [5] ; ours is the first study to combine these findings. The increase in mutation rate we found with higher previous-sample CD4 cell count, but not VL, could reflect a greater number of target cells for replication under drug pressure. Despite varying subtypes, the pattern of resistance mutations we found is similar to that in other studies of PI-based regimens [7, 23, [29] [30] [31] . I47A was often followed by V32I, and developing I47A was associated with a lower odds of developing I54V and vice versa. This has important consequences for third-line ART, as I47A confers intermediate-level resistance to darunavir and V32I is suggested as a key mutation for high-level resistance [32, 33] , whereas I54V is not known to affect darunavir response [13] . We also frequently observed the V82A mutation, thought to improve susceptibility to darunavir [34] .
We found that VL increased only modestly after failure, driven mostly by low adherence and development of PI mutations. Our finding of an initial relatively large increase in VL followed by a plateau in replication after I47A development is supported by in vitro evidence [33, 35] ; contrary to this L24I  V32I  M46I  M46L  I47A  I47V  G48V  I50L  I50V  F53L  I54V  Q58E  T74P  L76V  V82A  V82F  V82S  N83D  I84V  I85V literature, we did not find a difference in virus that also had the V32I mutation, although numbers were small. Other PI mutations had comparatively modest effects as observed elsewhere [36] , although not all studies have observed this effect [10] . The association between adherence and VL is unsurprising [37] , but its impact was relatively small. Other factors associated with VL after failure (age, time on first-line ART, time on second-line ART before failure) are possible surrogates for adherence.
This trial was designed pragmatically in 2008-2009 to test second-line options in settings without regular VL monitoring, which still remains limited in many areas in sub-Saharan Africa. We included PI monotherapy because, at that time, this was considered a potential second-line option for the public health approach [38, 39] , albeit with some risk, that merited testing in a randomized controlled trial. We included monitoring of outcomes and the DMC stopped the arm when it had been demonstrated definitively that PI monotherapy was not viable in this setting. At least 1 subsequent trial in sub-Saharan Africa again confirmed high rates of VL rebound with PI monotherapy and was stopped by a DMC [40] . Although PI monotherapy is clearly not an appropriate therapeutic option, our findings remain relevant for patients on combination therapy in sub-Saharan African programs. The resistance profile resembles that seen with combination PI regimens and is unlikely to be influenced by NRTIs, but the overall rate of Poisson model with time since failure, adherence, and subtype forced into the model. Other factors selected using backward elimination (exit P > .1). Factors not selected: age, sex, years on first-line therapy, CD4 count at switch to second-line therapy, proportion of VL >50 copies/mL, viremia copy-years, or time on second-line therapy before failure, VL in previous sample, or VL or CD4 second-line failure.
Abbreviations: CI, confidence interval; VL, viral load. a Included in model using fractional polynomials with 2 degrees of freedom (df) as week PI resistance development would likely be slowed with NRTIs (through direct effects on VL replication, or indirect effects on viral fidelity/fitness) [41] . Our results therefore represent a more extreme case than would likely have been seen in practice. Here, the second-line PI was standardized to lopinavir/ ritonavir. There are no comparable data for atazanavir in second-line therapy in program settings, although this is also a preferred PI in current WHO guidelines [2] . Although there are differences in mutation development between these PIs, our conclusion about likely success of an empirical switch to darunavir is also likely to apply to atazanavir failure in second-line therapy. Study strengths are its size (the largest longitudinal study investigating PI resistance following failure in low-income countries), monitoring approach (VL testing was not influenced by patients' status, removing a potential source of bias), and broad inclusion criteria. The key limitation is that patients were taking PI monotherapy, an ineffective second-line regimen [12, 40, 42] , as discussed above. Caution is needed in drawing conclusions beyond 40-48 weeks after failure due to smaller numbers in follow-up after this time and likely selective drop-out. We measured adherence by self-report, which may be inaccurate. We made assumptions around persistence/absence of resistance mutations to account for our sampling strategy, but results were similar in sensitivity analyses that explored alternative assumptions. Our sampling strategy may have led us to miss mutations that were selected and lost between weeks 48 and 96. However, mutations rarely disappeared in our data, suggesting that this is uncommon.
In summary, most patients develop virus with intermediate/high-level resistance within 1 year of failure when lopinavir/ritonavir is exposed to sustained VL replication without protection from other drugs. Even in this extreme situation, annual VL testing (current WHO recommendation) would identify failing patients at a time when most would likely still benefit from switching to darunavir as third-line therapy.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
Notes
Acknowledgments. We thank all of the participants and staff from all the centers participating in the EARNEST trial (see Appendix).
Financial support. Potential conflicts of interest. J. H. has received a grant for clinical trial support from the National Institutes of Health. A. K. has received personal fees from AbbVie and Gilead Sciences to attend HIV meetings, and speaker's fees from Gilead Sciences and Merck. J. A. has received personal fees for speaking and participation in advisory boards from Merck, ViiV, Gilead Sciences, Janssen, and Alexa. A. S. W. has received funding from Gilead Sciences to her institution for lecturing and from Janssen for data and safety monitoring board membership. N. P. has received personal fees for speaking (from AbbVie and Janssen), and chairing an advisory board (from Roche). N. P. has also received a grant from GSK for a tuberculosis trial, and provision of trial drugs from GSK and Sanofi. All other authors Linear mixed-effects model with random effects (unstructured covariance) for intercept and change over time. Adherence and subtype were forced into the model as key exposures of interest; other factors were selected using backward elimination (exit P > .1). Factors not selected: sex, CD4 count at switch to second-line therapy, proportion of VL >50 copies/mL on second-line therapy before failure, and CD4 count at previous sample. Viremia copy-years before failure not included due to co-linearity with time on second-line therapy before failure.
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; VL, viral load.
report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
